DC Circ. Decision May Lead To Tighter 340B Pharma Contracts

A D.C. Circuit decision last week holding that the federal 340B drug pricing program doesn't bar drugmakers from imposing contractual conditions on contract pharmacies could embolden them to impose tougher restrictions as...

Already a subscriber? Click here to view full article